Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover.

ABSTRACT: Non-small cell lung cancer (NSCLC) is a prevalent and fatal malignancy with a significant global impact. Recent advancements have introduced targeted therapies like tyrosine kinase inhibitors (TKIs) such as osimertinib, which have improved patient outcomes, particularly in those with EGFR mutations. Despite these advancements, acquired resistance to TKIs remains a significant challenge. Hence, one of the current research priorities is understanding the resistance mechanisms and identifying new therapeutic targets to improve therapeutic efficacy. Herein, we identified high expression of c-Met in osimertinib-resistant NSCLC cells, and depletion of c-Met significantly inhibited the proliferation of osimertinib-resistant cells and prolonged survival in mice, suggesting c-Met as an attractive t

SUBMITTER: Ma Y 

PROVIDER: S-EPMC11519634 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature